2025-01-15 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a diversified healthcare company, has significantly underperformed the S&P 500 (VOO) over the analyzed period.  While JNJ showed a cumulative return of 23.55%, VOO achieved a return of 112.74%. This represents a substantial divergence of -89.2%, placing it at the 8.4th percentile of its historical relative performance against the S&P 500 (based on the provided min/max range).

**2. Recent Price Movement:**

As of the last recorded data point:

* **Closing Price:** $144.75
* **5-day Moving Average:** $143.96
* **20-day Moving Average:** $144.55
* **60-day Moving Average:** $151.64

The price is slightly above the 5-day and 20-day moving averages, suggesting some short-term upward momentum. However, it's below the 60-day moving average, indicating a potential longer-term downtrend.

**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 50.88 – This indicates a neutral market sentiment, neither overbought nor oversold.
* **PPO (Price Oscillator):** 0.22 – A positive value suggests bullish momentum, although relatively weak.
* **20-day Relative Divergence:** +5.0 – Short-term upward momentum.
* **Expected Return:** -299.5% –  This extremely negative expected return relative to the S&P 500 over the long term (2+ years) is a significant red flag and requires further investigation to understand the underlying assumptions.  It suggests a substantial underperformance is anticipated relative to the market index.  The provided data does not offer enough context to understand this estimate's validity. The current price of $144.75 doesn't reflect any dramatic recent price swings (no evidence of sharp upturns or downturns).


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue       |
|------------|---------|---------------|
| 2024-10-23 | $1.12   | $22.47B       |
| 2024-07-25 | $1.95   | $22.45B       |
| 2024-05-01 | $1.35   | $21.38B       |
| 2024-02-16 | $1.68   | $21.39B       |
| 2023-10-27 | $10.32  | $21.35B       |

**Analysis:**  There's a significant drop in EPS from $10.32 in Q4 2023 to considerably lower figures in the following quarters. Revenue remains relatively stable, but the drastic decline in EPS requires further investigation to determine the underlying cause. This could indicate a potential problem with profitability.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |
| 2023-12-31 | $21.39B   | 68.23%        |
| 2023-09-30 | $21.35B   | 69.06%        |

**Capital and Profitability:**

| Quarter | Equity     | ROE           |
|---------|------------|---------------|
| 2024-09-30 | $70.16B   | 3.84%         |
| 2024-06-30 | $71.54B   | 6.55%         |
| 2024-03-31 | $70.02B   | 4.65%         |
| 2023-12-31 | $68.77B   | 5.89%         |
| 2023-09-30 | $71.23B   | 36.54%        |

**Analysis:** Profit margins remain consistently high, suggesting strong pricing power. However, ROE is highly volatile, with a particularly high value in Q3 2023 and much lower values in subsequent quarters. This inconsistency warrants further examination.


**7. Overall Analysis:**

JNJ's performance has significantly lagged the S&P 500, despite relatively stable revenue and high profit margins. The alarming drop in EPS, volatile ROE, and the extremely negative long-term expected return raise serious concerns. While short-term technical indicators show some positive momentum, the fundamental issues require further investigation before any investment decisions are made.  The -299.5% expected return needs clarification and validation.  Further analysis is needed to understand the discrepancies between revenue, profit margins, and EPS.  A detailed review of the company's financial statements and industry comparisons is crucial.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  The information presented is based on the data provided and may not reflect the complete picture.  Independent research and professional financial advice are recommended before making any investment decisions.
